These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2153576)

  • 1. The protonated form of 1-N6-etheno-[erythro-9-(2-hydroxy-3-nonyl)] adenine is identified at the active site of adenosine deaminase.
    Caiolfa VR; Gill D; Parola AH
    FEBS Lett; 1990 Jan; 260(1):19-22. PubMed ID: 2153576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the active site of adenosine deaminase by a pH responsive fluorescent competitive inhibitor.
    Caiolfa VR; Gill D; Parola AH
    Biophys Chem; 1998 Jan; 70(1):41-56. PubMed ID: 9474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
    J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of inhibition of calf intestinal adenosine deaminase by (+)- and (-)-erythro-9-(2-hydroxy-3-nonyl)adenine.
    Porter DJ; Abushanab E
    Biochemistry; 1992 Sep; 31(35):8216-20. PubMed ID: 1525161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
    Lambe CU; Nelson DJ
    Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Cristalli G; Eleuteri A; Franchetti P; Grifantini M; Vittori S; Lupidi G
    J Med Chem; 1991 Mar; 34(3):1187-92. PubMed ID: 2002459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
    Lum CT; Schmidtke JR; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473
    [No Abstract]   [Full Text] [Related]  

  • 8. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA
    J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase.
    Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P
    Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition.
    Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE
    Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA.
    Lupidi G; Cristalli G; Marmocchi F; Riva F; Grifantini M
    J Enzyme Inhib; 1985; 1(1):67-75. PubMed ID: 3916912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine.
    Vargeese C; Sarma MS; Pragnacharyulu PV; Abushanab E; Li SY; Stoeckler JD
    J Med Chem; 1994 Oct; 37(22):3844-9. PubMed ID: 7966142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine.
    Harriman GC; Poirot AF; Abushanab E; Midgett RM; Stoeckler JD
    J Med Chem; 1992 Oct; 35(22):4180-4. PubMed ID: 1433220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the chiral isomers of erythro- and threo-9-(2-hydroxy-3-nonyl)adenine on purine metabolism in sarcoma 180 cells.
    Chen SF; Stoeckler JD; Choi HS; Burgess FW; Marcaccio EJ; Steen PA; Berman SF; Parks RE; Panzica RP; Abushanab E
    Biochem Pharmacol; 1982 Dec; 31(24):3955-60. PubMed ID: 7159473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2's-hydroxy-3's-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors.
    Kandalkar SR; Ramaiah PA; Joshi M; Wavhal A; Waman Y; Raje AA; Tambe A; Ansari S; De S; Palle VP; Mookhtiar KA; Deshpande AM; Barawkar DA
    Bioorg Med Chem; 2017 Oct; 25(20):5799-5819. PubMed ID: 28951094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy.
    Singhal D; Anderson BD
    J Pharm Sci; 1998 May; 87(5):578-85. PubMed ID: 9572908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues.
    North TW; Cohen SS
    Proc Natl Acad Sci U S A; 1978 Oct; 75(10):4684-8. PubMed ID: 216993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum.
    Muraoka T; Katsuramaki T; Shiraishi H; Yokoyama MM
    Anal Biochem; 1990 Jun; 187(2):268-72. PubMed ID: 2382828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF).
    Lum CT; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-toxicity immunosuppression by specific inhibition of adenosine deaminase (ADA): prolongation of mouse skin grafts with erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
    Lum CT; Sutherland DE; Foker JE; Najarian JS
    Surg Forum; 1977; 28():320-2. PubMed ID: 364724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.